Trevena, Inc. (NASDAQ:TRVN – Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.24 and traded as low as $1.30. Trevena ...

3月19日，港股 创新药 企业云顶新耀（1952.HK）宣布，正式启动位于浙江嘉善工厂的伊曲莫德（VELSIPITY®）生产建设项目。这一举措将有力推动伊曲莫德的本地化生产进程，同时为公司的mRNA技术产业化战略奠定坚实基础。

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

脑转移现象在肺腺癌患者中并不罕见，尤其是在66.3%带有表皮生长因子受体（EGFR）突变的非吸烟患者中更是高达29%在初诊时已被检测到脑转移。这一数据让人不禁担忧，越来越多的患者在接受靶向治疗后，脑转移的发生率从初诊时的25%上升至45%。如何应对这一挑战，成为了医学界亟待研究的问题。

点击蓝字关注我们【导读】脑转移是表皮生长因子受体（epidermal growth factor receptor， ...

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Manipal Institute of Virology (MIV) celebrated its Annual Day and Alumni Meet 2025 at Dr TMA Pai Auditorium, MAHE, Manipal, ...

总的来说，该研究发现长寿个体在血浆中表现出较少的全身性缺氧相关代谢物和更多的抗氧化和抗炎代谢物，从而具有更健康的临床表型，包括更低的炎症参数以及更好的葡萄糖-脂质代谢和肝肾功能。简而言之，年轻的红细胞功能和代谢使长寿个体能够更好地对抗外周组织缺氧、炎 ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

为探究三阴性乳腺癌（TNBC）淋巴结转移机制，研究人员研究 MLPH 作用，发现其经特定轴抑制肿瘤进展，或为 TNBC 治疗提供新策略。 为了揭开 TNBC 淋巴结转移的神秘面纱，大连理工大学附属肿瘤医院（中国医科大学附属肿瘤医院、辽宁省肿瘤医院 & 研究所）等机构的研究人员踏上了探索之旅。他们的研究成果发表在《Journal of Translational Medicine》上，为 TNBC ...

What is CNM-Au8 for MS? CNM-Au8 is an oral therapy candidate being investigated as a potential disease-modifying treatment for relapsing and progressive forms of multiple sclerosis (MS). Developed ...

为探究 CXCR4 和 S1P?相互作用机制，首尔国立大学研究人员发现二者可形成异源二聚体，S1P/S1P?轴单向调节 CXCR4，为免疫细胞 ...